CircoMax Myco

RSS
Authorised
This medicine is authorised for use in the European Union.

Overview

CircoMax Myco is a veterinary vaccine used to protect pigs against two separate infections caused by porcine circovirus type 2 (PCV2) and Mycoplasma hyopneumoniae.

PCV2 infections can produce clinical signs such as weight loss or failure to grow, enlarged lymph nodes, difficulty in breathing, diarrhoea, pale skin and jaundice (yellowing of the skin).

Infection with the bacterium M. hyopneumoniae in pigs causes a disease of the airways called enzootic pneumonia. Affected pigs often have a cough and fail to thrive.

CircoMax Myco contains inactivated (killed) recombinant porcine circovirus and an inactivated strain of M. hyopneumoniae.

This EPAR was last updated on 03/12/2021

Authorisation details

Product details
Name
CircoMax Myco
Agency product number
EMEA/V/C/005184
Active substance
  • Inactivated Mycoplasma hyopneumoniae, strain P-5722-3
  • Inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (ORF2) protein
  • Inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b ORF2 protein
Species
Pigs (for fattening)
Anatomical therapeutic chemical veterinary (ATCvet) codes
QI09AL08
Publication details
Marketing-authorisation holder
Zoetis Belgium SA 
Date of issue of marketing authorisation valid throughout the European Union
09/12/2020
Contact address

Zoetis Belgium SA
Rue Laid Burniat 1
1348 Louvain-la-Neuve
Belgium

Product information

09/12/2020 CircoMax Myco - EMEA/V/C/005184 -

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Immunologicals for suidae

Therapeutic indication

Active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with PCV2 infection. Protection was demonstrated against porcine circovirus types 2a, 2b and 2d.

Active immunisation of pigs against Mycoplasma hyopneumoniae to reduce the lung lesions associated with Mycoplasma hyopneumoniae infection. 

Onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination. 

Duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination. 

In addition, vaccination has been shown to reduce body weight gain losses under field conditions.

Assessment history

Related content

How useful was this page?

Add your rating